Form 4: Dolby SVP Sells 3,000 Shares Under 10b5-1 Plan

Dolby Laboratories' SVP of Advanced Technology Group, Shriram Revankar, sold 3,000 shares of Class A Common Stock for $65.55 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Shriram Revankar, SVP of Advanced Technology Group at Dolby Laboratories, Inc. (DLB), disposed of 3,000 shares of Class A Common Stock.
• The transaction occurred on November 21, 2025, at a price of $65.55 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Revankar beneficially owns 67,435 shares of Class A Common Stock.
• A significant portion of the remaining holdings, 47,766 shares, are restricted stock units (RSUs) subject to forfeiture until they vest.

Sentiment

Score: 5

Explanation: A neutral score as this is a routine insider sale under a pre-arranged 10b5-1 plan, which is a common practice for executives and does not typically signal significant positive or negative news about the company's fundamentals.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than an immediate reaction to market conditions.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity stake of a senior executive in the company.
• A substantial portion of the remaining beneficial ownership consists of unvested restricted stock units, which are not fully owned until vesting.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

Insider transactions, particularly sales, are common for executives managing personal finances or diversifying portfolios. Sales under 10b5-1 plans are a standard practice for executives to sell shares systematically without being accused of trading on inside information. This specific transaction does not provide broader industry context.

Comparison to Industry Standards

• This is a routine insider transaction under a 10b5-1 plan. Such plans are standard practice across publicly traded companies for executives to manage their equity holdings. There are no specific comparable companies or projects mentioned in this filing to assess against global benchmarks.

Stakeholder Impact

• For shareholders, this is a routine insider sale under a 10b5-1 plan, which typically has minimal direct impact on company operations or strategy. It slightly reduces the direct equity alignment of one executive.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine insider sale under a pre-arranged 10b5-1 plan. Such transactions are common for executives managing personal finances and are generally not indicative of new material information about the company's performance or future prospects. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a "hold" position remains appropriate based solely on this filing.

Keywords

Dolby Laboratories, DLB, Shriram Revankar, Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, Executive Compensation, Restricted Stock Units